Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Receivables (2018 - 2025)

Historic Receivables for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $11.1 million.

  • Exagen's Receivables rose 1824.86% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 1824.86%. This contributed to the annual value of $7.8 million for FY2024, which is 1871.21% up from last year.
  • As of Q3 2025, Exagen's Receivables stood at $11.1 million, which was up 1824.86% from $14.3 million recorded in Q2 2025.
  • Exagen's Receivables' 5-year high stood at $17.0 million during Q3 2023, with a 5-year trough of $6.1 million in Q4 2022.
  • In the last 5 years, Exagen's Receivables had a median value of $9.7 million in 2021 and averaged $10.6 million.
  • Per our database at Business Quant, Exagen's Receivables skyrocketed by 8628.8% in 2023 and then plummeted by 4492.49% in 2024.
  • Quarter analysis of 5 years shows Exagen's Receivables stood at $9.7 million in 2021, then tumbled by 37.11% to $6.1 million in 2022, then grew by 8.2% to $6.6 million in 2023, then increased by 18.71% to $7.8 million in 2024, then surged by 41.67% to $11.1 million in 2025.
  • Its Receivables was $11.1 million in Q3 2025, compared to $14.3 million in Q2 2025 and $14.7 million in Q1 2025.